Skip to content

Editors

Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

Bill Steinman
Contributing Editor

GlaxoSmithKline target of China bribe probe

Chinese police this weekend reportedly detained GlaxoSmithKline managers in Shanghai, Beijing, and Changsha.

The British pharma also known as GSK said authorities are investigating whether some of its senior execs in China have committed ‘economic crimes.’

The Wall Street Journal reported last month that a whistleblower claimed GlaxoSmithKline’s China staff have committed ‘widespread bribery of doctors to prescribe drugs.’

GSK disclosed in earlier SEC filings that the DOJ and SEC contacted the company in 2010 about possible violations of the FCPA in China and other countries.

China police over the weekend in the city of Changsha, Hunan Province, posted a notice that they are investigating senior managers at GSK China for economic crimes.

Share this post

LinkedIn
Facebook
Twitter

Comments are closed for this article!